New Treatment for Cystic Fibrosis

Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, is a new drug for the treatment of the most common cystic fibrosis mutation.Serious adverse effects include elevated liver enzymes and an increased risk of cataracts.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research